Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch
Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2024-04, Vol.24 (4), p.e209-e210 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e210 |
|---|---|
| container_issue | 4 |
| container_start_page | e209 |
| container_title | The Lancet infectious diseases |
| container_volume | 24 |
| creator | Cooper, George Dolby, Heather W Berry, Karla Russell, Clark D |
| description | Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture was reported but might have been helpful to quantify disease severity and guide patient selection (appendix). Supplementary Material Supplementary appendix SABATO cohort (n=108) Real-world cohort (n=71) Age (years) 64·4 (SD 16·8) 63·2 (SD 17·6) Sex Male 71 (66%) 41 (57·7%) Female 37 (34%) 30 (42·3%) BMI (kg per m2) 27·6 (6·7) 28·3 (6·9), 3 missing data points Co-morbidities Moderate or severe liver disease 11 (10%) 8 (11·3%) Chronic renal failure 17 (16%) 7 (9·9%) End-stage renal failure 9 (8%) 4 (5·6%) Diabetes with end-organ damage 19 (18%) 13 (18·3%) Charlson comorbidity index 3 (IQR 1–5) 5 (IQR 2–7) Source of bacteraemia* Intravenous catheter 71 (66%) 31 (43·7%) Skin and soft-tissue infection 26 (24%) 17 (23·9%) Other† 5 (5%) 7 (9·9%) Unknown 6 (6%) 16 (22·5%) Resistance‡ Meticillin 6 (6%) 4 (5·6%) Clindamycin 12 (12%) 14 (19·7%) Co-trimoxazole 1 (1%) 4 (5·6%) Outcomes Attributable mortality 2 (2%) 4 (5·6%) 90-day survival rate 83·6% 84·5% Relapsing Staphylococcus aureus bacteraemia 3 (3%) 2 (2·8%) Table Comparison of cohort characteristics |
| doi_str_mv | 10.1016/S1473-3099(24)00065-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2929131398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309924000653</els_id><sourcerecordid>2929131398</sourcerecordid><originalsourceid>FETCH-LOGICAL-c388t-5a2db6c99070bfde1a9e87475864d15c3c5e85b8c581894b27e114d85cca71be3</originalsourceid><addsrcrecordid>eNqFkE1PGzEQhq2qqAlpfwLVSr3AYcFe27F9qhDiS0LiAD1b3tnZxtEmTm0vKP8ekwCHXjjNaPS8M6OHkCNGTxll87MHJhSvOTXmuBEnlNK5rPkXMi1jUQsh1dddv0cm5DClJaVMMSq-kQnXZdooMyWPl4P_61s_-LytQl9tXPa4zql69nlRPWS3WWyHAAFgTJUbI5bSOsgYHa68q_oQK3RxKOHohiqVGCy-k4PeDQl_vNUZ-XN1-XhxU9_dX99enN_VwLXOtXRN187BGKpo23fInEGthJJ6LjomgYNELVsNUjNtRNsoZEx0WgI4xVrkM3K837uJ4d-IKduVT4DD4NYYxmQb0xjGGTe6oL_-Q5dhjOvyneWUG8WEFLRQck9BDClF7O0m-pWLW8uofdVud9rtq1PbCLvTbnnJ_XzbPrYr7D5S754L8HsPYNHx5DHaBMUzYOcjQrZd8J-ceAEnMJHV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3039714540</pqid></control><display><type>article</type><title>Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Cooper, George ; Dolby, Heather W ; Berry, Karla ; Russell, Clark D</creator><creatorcontrib>Cooper, George ; Dolby, Heather W ; Berry, Karla ; Russell, Clark D</creatorcontrib><description>Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture was reported but might have been helpful to quantify disease severity and guide patient selection (appendix). Supplementary Material Supplementary appendix SABATO cohort (n=108) Real-world cohort (n=71) Age (years) 64·4 (SD 16·8) 63·2 (SD 17·6) Sex Male 71 (66%) 41 (57·7%) Female 37 (34%) 30 (42·3%) BMI (kg per m2) 27·6 (6·7) 28·3 (6·9), 3 missing data points Co-morbidities Moderate or severe liver disease 11 (10%) 8 (11·3%) Chronic renal failure 17 (16%) 7 (9·9%) End-stage renal failure 9 (8%) 4 (5·6%) Diabetes with end-organ damage 19 (18%) 13 (18·3%) Charlson comorbidity index 3 (IQR 1–5) 5 (IQR 2–7) Source of bacteraemia* Intravenous catheter 71 (66%) 31 (43·7%) Skin and soft-tissue infection 26 (24%) 17 (23·9%) Other† 5 (5%) 7 (9·9%) Unknown 6 (6%) 16 (22·5%) Resistance‡ Meticillin 6 (6%) 4 (5·6%) Clindamycin 12 (12%) 14 (19·7%) Co-trimoxazole 1 (1%) 4 (5·6%) Outcomes Attributable mortality 2 (2%) 4 (5·6%) 90-day survival rate 83·6% 84·5% Relapsing Staphylococcus aureus bacteraemia 3 (3%) 2 (2·8%) Table Comparison of cohort characteristics</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(24)00065-3</identifier><identifier>PMID: 38309279</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - therapeutic use ; Bacteremia ; Bacteremia - drug therapy ; Blood culture ; Catheters ; Clindamycin ; Comorbidity ; Cotrimoxazole ; Data points ; Diabetes mellitus ; End-stage renal disease ; Humans ; Kidney diseases ; Liver diseases ; Medical instruments ; Methicillin ; Methicillin-Resistant Staphylococcus aureus ; Missing data ; Prostheses ; Renal failure ; Staphylococcal Infections - drug therapy ; Staphylococcus aureus ; Survival</subject><ispartof>The Lancet infectious diseases, 2024-04, Vol.24 (4), p.e209-e210</ispartof><rights>2024 Elsevier Ltd</rights><rights>2024. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c388t-5a2db6c99070bfde1a9e87475864d15c3c5e85b8c581894b27e114d85cca71be3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/3039714540?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38309279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cooper, George</creatorcontrib><creatorcontrib>Dolby, Heather W</creatorcontrib><creatorcontrib>Berry, Karla</creatorcontrib><creatorcontrib>Russell, Clark D</creatorcontrib><title>Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture was reported but might have been helpful to quantify disease severity and guide patient selection (appendix). Supplementary Material Supplementary appendix SABATO cohort (n=108) Real-world cohort (n=71) Age (years) 64·4 (SD 16·8) 63·2 (SD 17·6) Sex Male 71 (66%) 41 (57·7%) Female 37 (34%) 30 (42·3%) BMI (kg per m2) 27·6 (6·7) 28·3 (6·9), 3 missing data points Co-morbidities Moderate or severe liver disease 11 (10%) 8 (11·3%) Chronic renal failure 17 (16%) 7 (9·9%) End-stage renal failure 9 (8%) 4 (5·6%) Diabetes with end-organ damage 19 (18%) 13 (18·3%) Charlson comorbidity index 3 (IQR 1–5) 5 (IQR 2–7) Source of bacteraemia* Intravenous catheter 71 (66%) 31 (43·7%) Skin and soft-tissue infection 26 (24%) 17 (23·9%) Other† 5 (5%) 7 (9·9%) Unknown 6 (6%) 16 (22·5%) Resistance‡ Meticillin 6 (6%) 4 (5·6%) Clindamycin 12 (12%) 14 (19·7%) Co-trimoxazole 1 (1%) 4 (5·6%) Outcomes Attributable mortality 2 (2%) 4 (5·6%) 90-day survival rate 83·6% 84·5% Relapsing Staphylococcus aureus bacteraemia 3 (3%) 2 (2·8%) Table Comparison of cohort characteristics</description><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Bacteremia</subject><subject>Bacteremia - drug therapy</subject><subject>Blood culture</subject><subject>Catheters</subject><subject>Clindamycin</subject><subject>Comorbidity</subject><subject>Cotrimoxazole</subject><subject>Data points</subject><subject>Diabetes mellitus</subject><subject>End-stage renal disease</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Liver diseases</subject><subject>Medical instruments</subject><subject>Methicillin</subject><subject>Methicillin-Resistant Staphylococcus aureus</subject><subject>Missing data</subject><subject>Prostheses</subject><subject>Renal failure</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcus aureus</subject><subject>Survival</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkE1PGzEQhq2qqAlpfwLVSr3AYcFe27F9qhDiS0LiAD1b3tnZxtEmTm0vKP8ekwCHXjjNaPS8M6OHkCNGTxll87MHJhSvOTXmuBEnlNK5rPkXMi1jUQsh1dddv0cm5DClJaVMMSq-kQnXZdooMyWPl4P_61s_-LytQl9tXPa4zql69nlRPWS3WWyHAAFgTJUbI5bSOsgYHa68q_oQK3RxKOHohiqVGCy-k4PeDQl_vNUZ-XN1-XhxU9_dX99enN_VwLXOtXRN187BGKpo23fInEGthJJ6LjomgYNELVsNUjNtRNsoZEx0WgI4xVrkM3K837uJ4d-IKduVT4DD4NYYxmQb0xjGGTe6oL_-Q5dhjOvyneWUG8WEFLRQck9BDClF7O0m-pWLW8uofdVud9rtq1PbCLvTbnnJ_XzbPrYr7D5S754L8HsPYNHx5DHaBMUzYOcjQrZd8J-ceAEnMJHV</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Cooper, George</creator><creator>Dolby, Heather W</creator><creator>Berry, Karla</creator><creator>Russell, Clark D</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>202404</creationdate><title>Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch</title><author>Cooper, George ; Dolby, Heather W ; Berry, Karla ; Russell, Clark D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c388t-5a2db6c99070bfde1a9e87475864d15c3c5e85b8c581894b27e114d85cca71be3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Bacteremia</topic><topic>Bacteremia - drug therapy</topic><topic>Blood culture</topic><topic>Catheters</topic><topic>Clindamycin</topic><topic>Comorbidity</topic><topic>Cotrimoxazole</topic><topic>Data points</topic><topic>Diabetes mellitus</topic><topic>End-stage renal disease</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Liver diseases</topic><topic>Medical instruments</topic><topic>Methicillin</topic><topic>Methicillin-Resistant Staphylococcus aureus</topic><topic>Missing data</topic><topic>Prostheses</topic><topic>Renal failure</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcus aureus</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cooper, George</creatorcontrib><creatorcontrib>Dolby, Heather W</creatorcontrib><creatorcontrib>Berry, Karla</creatorcontrib><creatorcontrib>Russell, Clark D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cooper, George</au><au>Dolby, Heather W</au><au>Berry, Karla</au><au>Russell, Clark D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2024-04</date><risdate>2024</risdate><volume>24</volume><issue>4</issue><spage>e209</spage><epage>e210</epage><pages>e209-e210</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Key cohort characteristics reported by the trial were similar in trial participants compared with possibly eligible real-world patients, although the median Charlson comorbidity index was lower in the trial cohort (table). No laboratory or physiological data from the time of the index blood culture was reported but might have been helpful to quantify disease severity and guide patient selection (appendix). Supplementary Material Supplementary appendix SABATO cohort (n=108) Real-world cohort (n=71) Age (years) 64·4 (SD 16·8) 63·2 (SD 17·6) Sex Male 71 (66%) 41 (57·7%) Female 37 (34%) 30 (42·3%) BMI (kg per m2) 27·6 (6·7) 28·3 (6·9), 3 missing data points Co-morbidities Moderate or severe liver disease 11 (10%) 8 (11·3%) Chronic renal failure 17 (16%) 7 (9·9%) End-stage renal failure 9 (8%) 4 (5·6%) Diabetes with end-organ damage 19 (18%) 13 (18·3%) Charlson comorbidity index 3 (IQR 1–5) 5 (IQR 2–7) Source of bacteraemia* Intravenous catheter 71 (66%) 31 (43·7%) Skin and soft-tissue infection 26 (24%) 17 (23·9%) Other† 5 (5%) 7 (9·9%) Unknown 6 (6%) 16 (22·5%) Resistance‡ Meticillin 6 (6%) 4 (5·6%) Clindamycin 12 (12%) 14 (19·7%) Co-trimoxazole 1 (1%) 4 (5·6%) Outcomes Attributable mortality 2 (2%) 4 (5·6%) 90-day survival rate 83·6% 84·5% Relapsing Staphylococcus aureus bacteraemia 3 (3%) 2 (2·8%) Table Comparison of cohort characteristics</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>38309279</pmid><doi>10.1016/S1473-3099(24)00065-3</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2024-04, Vol.24 (4), p.e209-e210 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2929131398 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Anti-Bacterial Agents - therapeutic use Bacteremia Bacteremia - drug therapy Blood culture Catheters Clindamycin Comorbidity Cotrimoxazole Data points Diabetes mellitus End-stage renal disease Humans Kidney diseases Liver diseases Medical instruments Methicillin Methicillin-Resistant Staphylococcus aureus Missing data Prostheses Renal failure Staphylococcal Infections - drug therapy Staphylococcus aureus Survival |
| title | Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T07%3A46%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Eligibility%20of%20patients%20with%20Staphylococcus%20aureus%20bacteraemia%20for%20early%20oral%20switch&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Cooper,%20George&rft.date=2024-04&rft.volume=24&rft.issue=4&rft.spage=e209&rft.epage=e210&rft.pages=e209-e210&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(24)00065-3&rft_dat=%3Cproquest_cross%3E2929131398%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3039714540&rft_id=info:pmid/38309279&rft_els_id=S1473309924000653&rfr_iscdi=true |